|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-08
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-04
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-05
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis
|
5R01CA168717-05
|
$323,700
|
ELEFTERIOU, FLORENT
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
1R01CA215452-01
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-01S1
|
$14,309
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
5R01CA215452-02
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-04
|
$336,565
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-04
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
NCOA6, A Novel Tumor Suppressor of Endometrial Cancer
|
5R01CA193455-03
|
$86,504
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
1R03CA215940-01
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
5R03CA215940-02
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-02
|
$352,363
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|